CSF2 and melanoma: In the pivotal phase III OPTiM trial comparing T-Vec to granulocyte-macrophage colony-stimulating factor (GM-CSF) in 436 patients with unresectable stage IIIB-IV melanoma, deep vein thrombosis was reported as a grade 3–4 adverse event in 1.7% of patients receiving T-Vec [105].